Published:
ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results
TUCSON, Ariz., May 15 /PRNewswire-FirstCall/ -- ImaRx Therapeutics, Inc.
(Nasdaq: IMRX), a biopharmaceutical company developing and commercializing
therapies for vascular disorders, today reported financial results for the
first quarter ended March 31, 2008 and discussed recent corporate highlights.
Corporate Highlights:
-- Entered into agreement with Abbott Laboratories satisfying remaining
debt obligation under non-recourse promissory note issued in connection
with the Company's urokinase acquisition.
-- Signed letter of intent to sell urokinase inventory and related assets
to Microbix Biosystems for $17 million in cash: $12 million at closing
and $5 million upon achievement of an inventory stability milestone.
-- Identified strategic funding to continue advancement of its core
SonoLysis program upon closing of urokinase divestiture with Microbix
Biosystems.
Bradford A. Zakes, President and CEO of ImaRx stated, "Through the
satisfaction of our debt obligation with Abbott under favorable terms and the
pending divestiture of our urokinase asset to Microbix, we will have
successfully gained access to operating capital that is non-dilutive to our
shareholders. Taken together, these events have provided us the strategic
alternative to continue the advancement of our core SonoLysis technology
within ImaRx."
Financial Results
Revenue for the first quarter ended March 31, 2008 rose to $1.9 million
from $1.2 million for the first quarter ended March 31, 2007. Increased sales
of urokinase, which ImaRx began commercializing in October 2006, drove the
revenue increase for the quarter.
Net loss for the first quarter of 2008 was $2.5 million compared to a net
loss of $2.4 million for the same period last year. This change was primarily
a result of increased selling, general and administrative expenses offset
partially by increased urokinase sales. Net loss per share attributable to
common shareholders for the first quarter of 2008 was $0.25 based on weighted
average shares of approximately 10.0 million, compared to net loss per share
attributable to common shareholders in the same period last year of $1.09
based on weighted average shares of approximately 2.6 million.
Cost of product sales for the first quarter of 2008 totaled $0.8 million
compared to $0.5 million for the first quarter of 2007. The cost of product
sales includes the price paid to acquire the urokinase inventory as well as
labeling costs directly incurred in bringing the product to market.
Research and development expenses for the first quarter of 2008 increased
to $1.6 million from $1.5 million in the prior year period. This increase was
principally a result of increased outside contract work performed on grants
and stock-based compensation expense, partially offset by reduced contract
manufacturing and pre-clinical study costs.
General and administrative expenses for the first quarter of 2008
increased to $2.0 million from $1.4 million for the same period last year
resulting mainly from an increase in outside accounting and audit fees related
to maintaining public company status, expenses related to marketing materials
for the re-branding of urokinase under the Kinlytic(TM) brand name, salaries
for additional sales and general administrative staff offset partially by a
decrease in amortization expense due to the trade name being fully amortized
prior to 2008.
On March 31, 2008, ImaRx had $10.3 million in cash and cash equivalents
compared to $12.9 million in cash and cash equivalents on December 31, 2007.
The decrease in the cash balance was primarily related to cash used in
performing operating activities. Subsequent to the end of the quarter, the
Company paid $5.2 million to satisfy all outstanding liabilities to Abbott
Laboratories, including the $10.8 million balance on the $15 million
non-recourse note. ImaRx also recently signed a letter of intent to sell its
urokinase assets to Microbix Biosystems for $17 million in cash. Since
signing the agreement with Abbott and assuming the transaction with Microbix
closes, management believes that there will be sufficient cash resources for
at least the next 12 months.
Conference Call and Webcast Information
Management will host a conference call to review financial results for the
quarter ended March 31, 2008 and recent business developments. The call is
scheduled for today, May 15, 2008, at 5:00 p.m. Eastern Time (2:00 p.m.
Pacific Time). To participate in the live conference call, U.S. residents
should dial 877-407-4018, and international callers should dial 201-689-8471.
Alternatively, log on to www.imarx.com to access a live webcast of the call.
Please connect to the Investor section of ImaRx's website several minutes
prior to the start of the live conference call to ensure adequate time for any
software download that may be necessary. To access the 48-hour telephone
replay, U.S. residents should dial 877-660-6853, and international callers
should dial 201-612-7415. The account number for the replay is 3055, and the
conference ID number is 284385. A replay of the webcast will also be
available on www.imarx.com 14-days following the call.
About ImaRx Therapeutics
ImaRx Therapeutics is a biopharmaceutical company developing and
commercializing therapies for vascular disorders. The Company's research and
development efforts are focused on therapies for stroke and other vascular
disorders using its proprietary microbubble technology. The Company's
commercialization efforts are currently focused on its product, urokinase, for
the treatment of acute massive pulmonary embolism.
About SonoLysis
ImaRx's SonoLysis program involves the administration of its proprietary
MRX-801 microbubbles and ultrasound to break up blood clots and restore blood
flow to oxygen deprived tissues. The sub-micron size of MRX-801 microbubbles
may allow them to penetrate a blood clot, so that when ultrasound is applied
their expansion and contraction, or cavitation, can break the clot into very
small particles. This technology was most recently evaluated in a Phase I/II
clinical trial in combination with tPA in patients suffering from acute
ischemic stroke.
About Urokinase
Urokinase is a thrombolytic or clot-dissolving agent indicated for the
treatment of acute massive pulmonary embolism, or blood clots in the lungs.
The product has been commercialized for more than 20 years and has been
administered to greater than four million patients. In 2006, ImaRx acquired
urokinase and all related assets, including an approximate four-year supply of
inventory, cell lines and manufacturing rights to the drug. Since October
2006, ImaRx has been selling its urokinase inventory in the U.S. market where
it is estimated to be listed on pharmacy formularies at approximately 700
acute care hospitals and has generated $16.7 million in net proceeds through
the first quarter of 2008.
Cautionary Statement For The Purpose Of The "Safe Harbor" Provisions Of The
Private Securities Litigation Reform Act of 1995
Note: Statements made in this press release which are not historical in
nature constitute forward-looking statements for purposes of the safe harbor
provided by the Private Securities Litigation Reform Act of 1995. Such
statements include those related to the Company's expectation that: it will
continue advancement of its core SonoLysis program upon closing of urokinase
divestiture with Microbix Biosystems; it will close the transaction with
Microbix; and the Company's belief that it will have sufficient cash resources
for at least the next 12 months. These statements are based on management's
current expectations and beliefs and are subject to a number of factors and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. A more complete description of
these risks and the event that may cause such events not to occur can be found
in the Company's filings with the Securities and Exchange Commission. All
information in this press release is as of May 15, 2008, and the Company
undertakes no duty to update this information.
Contacts:
The Ruth Group (Investors/Media)
Sara Ephraim/Jason Rando
sephraim@theruthgroup.com
jrando@theruthgroup.com
ImaRx Therapeutics, Inc.
Consolidated Statements of Operations
(in thousands except share and per share data)
Three Months Ended
March 31
2007 2008
(unaudited)
Revenues:
Product sales, net $1,086 $1,849
Research and development 122 95
Total operating revenue 1,208 1,944
Costs and expenses:
Cost of product sales 461 834
Research and development 1,541 1,567
General and administrative 1,420 1,994
Total cost and expenses 3,422 4,395
Operating loss (2,214) (2,451)
Interest and other income, net 41 94
Interest expense (225) (173)
Net loss (2,398) (2,530)
Accretion of dividends on preferred stock (441) -
Net loss attributed to common stockholders $(2,831 $(2,530)
Net loss per share:
- Basic and diluted $(1.09) $(0.25)
Shares used in computing net loss per share:
- Basic and diluted 2,605,915 10,046,683
ImaRx Therapeutics, Inc.
Selected Balance Sheet Data (in thousands)
December 31, March 31,
2007 2008
ASSETS (unaudited)
Current assets:
Cash and cash equivalents $12,861 $10,293
Restricted cash 388 -
Accounts receivable, net 349 124
Inventory 11,138 10,791
Inventory subject to return 2,560 2,144
Prepaid expenses and other 589 320
Total current assets 27,885 23,672
Long-term assets:
Property and equipment, net 1,170 1,046
Intangible assets, net 1,633 1,459
Other assets 19 19
Total assets $30,707 $26,196
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $1,277 $1,213
Accrued expenses 837 593
Accrued chargebacks and administrative fees 1,317 1,251
Deferred revenue 5,373 4,471
Notes payable 11,698 10,749
Other - 40
Total current liabilities 20,502 18,317
Other long-term liability - -
Total liabilities 20,502 18,317
Total stockholders' equity 10,205 7,879
Total liabilities and stockholders' equity $30,707 $26,196
SOURCE ImaRx Therapeutics, Inc.
Copyright © 2008, PRNewswire
Copyright © 2008, NewsBlaze,
Daily NewsTags: ,MTC,BIO,HEA,ERN,CCA,AZ-ImaRx-1Q-08-Earns
_ _Is your favorite bookmark site missing?
Ask for it.
Search News
Daily News
